skip page navigation Oregon State University
College of Pharmacy
DURM » DUR Board » Evaluations

Drug Use Evaluations

Topic

 

Date Posted

Drug Use Evaluation: Methadone   5/09
Pegylated-Interferon Ribavirin Prior Authorization Policy Analysis   5/08
Oral Transmucosal Fentanyl Citrate (Actiq) Prior Authorization Policy Analysis   3/08
Drug Use Evaluation: Smoking Cessation   3/08
Oregon Health Plan Drug Copay Analysis   6/22/07
Evaluation of OHP FFS Contracted Mail-Order Pharmacy Program   6/22/07
Newer Antiepileptic Drugs   5/31/07
Chronic Benzodiazepine Use Among Subjects 65 and Older   3/21/07
Chronic Benzodiazepine Use In Children and Adolescents   3/21/07
Duplicate Atypical Antipsychotic DUE   3/21/07
Acetaminophen Overuse   3/15/07
Dose Optimization Report - Follow Up   12/06/06
Long-Acting Beta Agonist (LABA)   12/06/06
Transdermal Fentanyl   12/06/06
Sedative Use in Children   9/07/06
Dose Optimization Report   5/18/06
Evaluation of a Pilot PDL Conversion Program   2/24/06
Pegylated-Interferon/Ribavirin Utilization Analysis   5/25/04
Antinauseants Quantity Limit Policy Impact Analysis   2/24/04
Gabapentin PA Policy Impact Analysis   2/24/04
Sedative Hypnotic Quantity Limit Policy Impact Analysis   2/24/04
Carisprodolol Quantity Limit Policy Impact Analysis   2/24/04
ABX Use in URI   11/18/03
Drug Utilization Review: Palivizumab (Synagis; Medimmune)   10/01/03
 
 

New Drug Evaluations

Topic

 

Date Posted

Milnacipran (Savella)   05/21/09
Emend   10/13/03
FluMist   10/13/03
Xolair   10/01/03


Evaluations Archive




Disclaimer: The information contained on our Web site and news list has been prepared in good faith to provide accurate and impartial information to DMAP providers. Clinical recommendations are based on published, peer-reviewed medical literature. Although every attempt has been made to ensure that the information contained herein is timely and accurate, users should consult all available sources of drug information before making decisions regarding patient care. This information is advisory only and is not intended to replace FDA-approved labeling information, or sound clinical judgment, in the delivery of health care services. Please also note that the prescribing trends provided are highly dependent on time and method of database query. The user of this information assumes entire risk.